SAB members

Jean-Louis Junien

Chaiman of the Scientific Advisory Board and former Director of Inventiva’s board of directors and senior pharmaceutical executive with an extensive experience in the pharmaceutical industry.

Manal Abdelmalek, MD

Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. She is a standing member of the NASH Clinical Research Network (NASH CRN).

Glen Clack, MD

Honorary Professor of Translational Medicine of the Department of Oncology and Metabolism at the University of Sheffield and previously Senior Medical Director of the Oncology Translational Medicine Unit of Astra Zeneca.

Kenneth Cusi, MD

Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville. His grants focus on cutting-edge research in adult endocrinology, diabetes and metabolism, both on clinical and basic research aspects related to the role of obesity and lipotoxicity in the development of Type 2 diabetes and its complications, in particular, the pathogenesis of NAFLD.

Sven Francque, MD

Professor of Medicine at the Faculty of Medicine and Health Sciences at the University of Antwerp and Chairman of the Department of Gastroenterology and Hepatology. His research unit focuses on the pathophysiological mechanisms of NASH.

Arun J. Sanyal, MD

Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. He also serves as Chairman of the National Institutes of Health (NIH) NASH Clinical Research Network, the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) consortium and the Liver Forum for NASH and Fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of cirrhosis and End-stage Liver Disease.

Andrew Shenker, MD

Expert in rare diseases and gene therapy. Doctor Shenker is a pediatric physician-scientist with over 20 years of experience in academic, biotech and pharmaceutical industry settings. Most recently, he serves as the Vice President of GlaxoSmithKline Rare Diseases. He has expertise in cell signaling and disease pathophysiology, clinical pharmacology, biomarker strategy, and in the clinical development of novel treatments for rare metabolic and neurological diseases, including lysosomal storage disorders.

Gérard Zalcman, MD

Professor of Medecine, Head of the Thoracic Oncology Department of Bichat Hospital, Paris (Paris-Diderot University), and member of the U830 INSERM laboratory, “Genetics & Biology of cancers“, at the Research Centre of the Curie Institute.

Elisabetta Bugianesi, MD

Professor of Gastroenterology and Scientific Director of the Department of Medical Sciences at the University of Turin in Italy. Her research focuses on the pathophysiological mechanisms of NASH, the natural history of the disease including Hepatocellular carcinoma (HCC) and the development of non-invasive markers of fibrosis.

Trever Bivona, MD, PhD

Professor of Medicine and Cellular and Molecular Pharmacology at the UCSF Helen Diller Family Comprehensive Cancer Center and Senior Investigator at the Chan-Zuckerberg Biohub. Dr. Bivona’s research team focuses on deciphering the key signal transduction pathways and molecular features driving cancer growth, evolution and drug resistance.